Enter psychedelics like ketamine, psilocybin, and MDMA, which are being explored as tools to access and process these buried experiences. They offer a non-linear, ego-dissolving space where ...

Discover how the brain's most abundant neurotransmitter, glutamate, is revolutionizing psychiatry and offering new hope for ...

This week, the US Food and Drug Administration expanded its approval of Spravato, an antidepressant nasal spray. The drug, made by Johnson & Johnson, is now cleared for use as the only standalone ...

When Therapy Alone Isn't Enough, Options Like TMS and SPRAVATO® Provide Additional Relief OAK BROOK, Ill., April 8, 2025 ...

Bausch Health's Aplenzin could revolutionize TRD care, addressing a $3B market opportunity while aiding BHC stock's financial ...

The FDA has cleared Auvelity (dextromethorphan ... That status goes to Johnson & Johnson's Spravato (esketamine), which was approved in March 2019 and is administered as a nasal spray twice ...

In 2019, the U.S. Food and Drug Administration (FDA) approved Spravato (esketamine), which offers rapid relief of depressive symptoms. However, it necessitates careful medical supervision because ...

Johnson & Johnson’s Q1 2025 earnings reveal growth in sales and EPS, boosted by MedTech and Pharma. Click for my updated look at JNJ and its most recent news.

The trailer for Season 27 of South Park has been released, and the animated satirical sitcom appears to have a new target: Elon Musk. Newsweek has reached out to X outside of normal working hours via ...

Doug Drysdale, CEO of Cybin opens up to Invezz about the benefits of psychedelics based drugs, why psychedelic stocks are struggling and how Big Pharma may soon get involved in the sector.